Fractional CFO for Biotech Startups: 7 Smart Ways to Extend Runway and Raise Capital

Biotech founders are usually scientists first. They know how to design experiments, interpret data and build a compelling therapeutic or platform thesis. But the moment a company raises its first dollar, it also becomes a business that must manage burn rate, vendor contracts, equity, grants, audits and a board of investors who expect accurate, timely financial information. In an industry where it can take years and many millions of dollars to reach a value-creating milestone, financial mistakes are expensive — and sometimes fatal.

That’s why pre-revenue and early-revenue life sciences companies across the United States are hiring a fractional CFO for biotech startups. You get a senior finance leader who understands milestone-based financing, clinical and preclinical budgets, CRO and CDMO contracts, non-dilutive funding, 409A valuations and investor reporting, working with you part-time and at a fraction of the cost of a full-time CFO.

This guide explains what a fractional CFO does for a biotech company, the metrics that matter, the warning signs you need help, typical pricing in 2026 and how to get started. Ready now? Book a free consultation or email contact@nadeemacademy.com.

What Is a Fractional CFO for Biotech Startups?

A fractional CFO is an experienced chief financial officer who works with several companies part-time. A fractional CFO for biotech startups specializes in the unique economics of life sciences: long development timelines, milestone-driven value creation, heavy outsourced R&D, complex equity structures, non-dilutive funding and a fundraising process that depends on credibility with specialist investors.

Most early biotech companies have an outsourced bookkeeper and a CPA for tax filings. Some have an interim controller. What’s usually missing is a strategic finance leader who connects the science plan with the financial plan and answers the questions that decide whether the company survives to its next inflection point:

• How many months of cash do we really have, including committed vendor contracts?
• What does it cost to reach our next scientific or regulatory milestone?
• How much should we raise, when, and at what dilution?
• Which non-dilutive funding sources can extend our runway?
• Are our grant costs, R&D accruals and equity accounted for correctly?
• Are we ready for investor due diligence and a first audit?

For a general introduction to the role, read what a fractional CFO does, or compare options in fractional CFO vs full-time CFO.

Why Biotech Finance Is Different

1. Value is created by milestones, not revenue

Most businesses are valued on revenue and profit. Biotech companies are valued on scientific and regulatory progress: validating a target, completing IND-enabling studies, filing an IND, reading out Phase 1 or Phase 2 data, or securing a partnership. Every financial decision must be tied to reaching the next milestone before cash runs out.

2. Long timelines and high burn

Drug development can take many years, and even early preclinical programs require significant spending on lab space, equipment, specialized talent, animal studies and manufacturing. Burn rate can jump sharply as programs move toward the clinic.

3. Heavy reliance on outsourced partners

Many startups run lean internal teams and outsource work to contract research organizations (CROs), contract development and manufacturing organizations (CDMOs) and academic collaborators. These contracts often involve milestone payments, pass-through costs and complex accrual accounting.

4. Multiple funding sources with different rules

Biotech companies commonly combine venture capital, angel investors, convertible notes or SAFEs, government grants, foundation funding and strategic partnerships. Each source comes with its own reporting requirements and restrictions on how money can be spent.

5. Sophisticated, demanding investors

Life sciences investors expect detailed operating plans, scenario analysis, clean cap tables and professional board reporting. A founder who can’t answer financial questions quickly and accurately loses credibility in the room.

6. Equity is a major form of compensation

Scientific talent is scarce and expensive, so stock options are a critical recruiting tool. That brings 409A valuations, stock-based compensation expense and careful cap table management.

9 Signs Your Biotech Startup Needs a Fractional CFO

If several of these apply, a fractional CFO for biotech startups can protect your runway and your credibility. Talk to us today.

What a Fractional CFO Does for Biotech Startups

We work alongside your existing bookkeeper or accounting team, and we can help you upgrade your books if they’re not investor-ready. Learn how CFO support differs from bookkeeping in our fractional CFO vs bookkeeper guide.

Biotech Metrics Every Founder Should Track

Metric	What It Measures	Why It Matters
Cash Runway	Months of operation remaining at the current burn	The single most important number in any pre-revenue biotech
Net Burn Rate	Monthly cash out minus cash in	Shows how fast capital is being consumed
Committed Spend	Signed but unpaid contracts (CROs, CDMOs, leases)	True runway is shorter than bank balance ÷ burn suggests
Cost to Next Milestone	Total spend required to reach the next value inflection	Determines how much to raise and when
R&D vs G&A Ratio	Research spend compared with overhead	Investors want most capital going into science
Budget vs Actual by Program	Variance for each research program	Early warning of overruns and delays
Non-Dilutive Funding %	Grants and credits as a share of total funding	Measures how efficiently you extend runway without dilution
Fully Diluted Ownership	Founder and investor ownership after options and convertibles	Key for negotiating future rounds

Understanding working capital and cash dynamics is just as important for a startup as it is for a mature company, because payment timing on large vendor contracts can create sudden cash crunches.

Runway and Milestone-Based Budgeting

In biotech, the budget is a strategic document, not an accounting exercise. A fractional CFO for biotech startups builds your budget around the milestones that create value, working backward from the data readouts or regulatory steps investors care about.

A milestone-based budget answers four questions: What must we accomplish? What will it cost? How long will it take? And how much buffer do we need if experiments fail, timelines slip or vendors raise prices? Experienced life sciences investors often expect companies to raise enough capital to reach the next milestone with a meaningful cushion, because science rarely proceeds exactly on schedule.

We build runway forecasts that include:

• Headcount plans with fully loaded costs, including benefits, payroll taxes and recruiting.
• Lab space, equipment leases and consumables.
• CRO, CDMO and consultant contracts, including milestone-based payments.
• Grant receipts and R&D tax credit refunds timed realistically.
• Base, upside and downside scenarios showing what happens if a study is delayed or a raise takes longer than planned.

With this plan in place, founders can make informed trade-offs: which programs to prioritize, when to hire, and where to cut if runway gets tight. A fractional CFO for biotech startups also sets up monthly budget-versus-actual reviews so surprises are caught early rather than at the next board meeting.

Fundraising: Seed to Series B

Raising capital is one of the most time-consuming responsibilities of a biotech CEO, and financial preparation has a major influence on both speed and valuation. A fractional CFO for biotech startups supports every step of the process:

1. Capital strategy: decide how much to raise, which milestones the round funds and which investor types fit your stage.
2. Financial model: build a clear, defensible operating model that ties science timelines to cash needs.
3. Use of funds: show investors exactly how their capital will be deployed and what it will achieve.
4. Data room: organize financial statements, cap table, contracts, grant documents and tax filings.
5. Term sheet analysis: model dilution, liquidation preferences, option pool shuffles and future round scenarios.
6. Closing and reporting: manage funds flow and set up the investor reporting cadence after close.

We also help with bridge financing, convertible notes and SAFEs, including how their conversion terms affect ownership in the next priced round. For more on how CFO support accelerates funding, see our guide to hiring a fractional CFO.

Grants, Non-Dilutive Funding and R&D Tax Credits

Non-dilutive funding is one of the most powerful ways to extend runway without giving up ownership. The SBIR and STTR programs fund early-stage research at small US companies across agencies including the National Institutes of Health. Foundations, disease advocacy groups and state programs also offer grants for life sciences innovation.

Winning a grant is only half the job. Grants require careful budgeting, cost tracking, allowable-cost compliance, time and effort reporting, and timely drawdowns. Poor grant accounting can lead to disallowed costs, delayed payments or problems in future applications. A fractional CFO for biotech startups sets up systems to track grant spending separately, prepares financial reports for funding agencies and ensures indirect cost rates are applied correctly.

The federal R&D tax credit can also provide valuable cash. Qualified small businesses may be able to apply a portion of the credit against payroll taxes, which is useful for pre-revenue companies that don’t yet owe income tax. The IRS explains the payroll tax election for qualified small businesses. We coordinate with your CPA to document qualified research expenses and make sure the credit is claimed correctly. Always confirm eligibility and tax treatment with your tax advisor.

Managing CROs, CDMOs and Vendor Spend

Outsourced research and manufacturing often represent the largest share of a biotech startup’s spending. Contracts can include upfront deposits, milestone payments, pass-through costs, change orders and cancellation terms. Without active management, costs drift upward and committed spend quietly consumes runway.

A fractional CFO for biotech startups helps you:

• Review vendor proposals and compare pricing across CROs and CDMOs.
• Negotiate payment terms that align with your cash position and milestones.
• Track committed, invoiced and paid amounts for every contract.
• Estimate monthly R&D accruals based on work performed, not just invoices received.
• Monitor change orders and flag scope creep early.
• Build purchase approval workflows so spending stays within budget.

Accurate accruals are especially important. Investors and auditors expect R&D expenses to be recorded when the work is performed, and incorrect accruals can distort your burn rate and financial statements.

Accounting, Audits and Compliance

As biotech companies raise larger rounds, sign partnership agreements or prepare for potential acquisition, they often need audited financial statements. A first audit is much smoother when your books are already on an accrual basis with documented accounting policies.

A fractional CFO for biotech startups prepares you by establishing monthly close procedures, R&D accrual methodologies, stock-based compensation accounting, grant revenue recognition, lease accounting and internal controls appropriate for your size. We coordinate with auditors, 409A valuation providers and tax advisors so founders aren’t pulled away from the science.

We also help manage equity administration, including option grants, vesting schedules, exercises and cap table updates, so your ownership records are always accurate and ready for due diligence. For a primer on the basics, read our guide to bookkeeping vs accounting.

Licensing, Partnerships and Strategic Deals

For many biotech companies, a partnership with a larger pharmaceutical or medtech company is the most important financing event of all. Licensing deals, co-development agreements and option-to-acquire structures can bring upfront payments, milestone payments, research funding and royalties — along with validation that makes future fundraising easier. But these deals are complex, and founders who don’t understand the economics can give away too much value.

A fractional CFO for biotech startups helps you evaluate proposed deal terms by modeling the value of upfront cash versus back-ended milestones, the probability of reaching each milestone, royalty tiers, cost-sharing obligations and how the deal affects your runway and future fundraising. We translate a term sheet into a clear net present value comparison so the leadership team and board can weigh options objectively.

Partnership revenue also brings accounting complexity. Upfront payments, milestone payments and research funding may need to be recognized over time under revenue recognition rules, and incorrect treatment can create problems during an audit or future financing. We work with your auditors to document the accounting approach clearly from the start.

Building Finance Infrastructure That Scales

Early biotech companies often start with a simple setup: a bookkeeper, a basic accounting system, spreadsheets for budgets and a shared drive for contracts. That works for a few months, but as headcount, programs and vendors grow, the cracks appear. Invoices get approved late, accruals are estimated inconsistently and nobody can answer a board member’s question without a day of digging.

A fractional CFO for biotech startups designs a finance infrastructure that grows with you. That typically includes a cloud accounting system with a chart of accounts organized by program and department, a purchase order and approval workflow for vendor spend, expense management tools, a contract database that tracks committed spend, and a reporting package that updates each month with minimal manual work.

We also define who does what. Many startups combine an outsourced bookkeeper for transaction processing with a fractional CFO for strategy and oversight, adding a controller as the company grows. This layered model keeps costs proportionate to the company’s stage while ensuring there is senior judgment behind every number presented to investors. When the company eventually needs full-time finance staff, we help write job descriptions, interview candidates and hand over systems smoothly.

Strong infrastructure pays off most during due diligence. When an investor, partner or acquirer asks for detailed information, a well-organized company responds in hours instead of weeks — and that responsiveness builds the confidence that closes deals.

Fractional CFO vs Full-Time CFO for a Biotech Startup

Factor	Fractional CFO	Full-Time CFO
Annual cost	About $42,000–$144,000	Often $300,000+ with equity, bonus and benefits
Equity required	Usually none or minimal	Meaningful option grant expected
Speed to start	Days to weeks	Months of recruiting
Flexibility	Scale up during fundraising, down afterward	Fixed cost regardless of workload
Best fit	Pre-seed through Series B, pre-clinical and early clinical	Later-stage clinical, pre-IPO or commercial companies

For most early-stage companies, a fractional CFO for biotech startups delivers senior expertise exactly when it’s needed, while preserving cash and equity for the science. As the company approaches later-stage trials or a public offering, the fractional CFO can help recruit and transition to a full-time CFO.

How Much Does a Fractional CFO for Biotech Startups Cost?

Many companies increase support temporarily during an active raise and scale back afterward. See our detailed guide to fractional CFO cost and pricing models.

Illustrative Example: A Preclinical Therapeutics Startup

This is an illustrative example, not a specific client. Picture a preclinical therapeutics company with a small team, a seed round in the bank and one SBIR Phase I grant. The founders believe they have 18 months of runway and plan to raise a Series A after completing IND-enabling studies.

When a fractional CFO for biotech startups reviews the numbers, committed CRO contracts, planned hires and a manufacturing deposit reveal that true runway is closer to 13 months — not enough to reach the milestone with any buffer. The CFO reprioritizes one secondary program, renegotiates payment terms with a CDMO, sets up grant cost tracking to accelerate drawdowns and documents R&D tax credit eligibility with the company’s CPA.

The result in a scenario like this: runway extended by several months, a milestone-based plan investors can trust, and a Series A process launched early from a position of strength rather than urgency.

What a Typical Month Looks Like

1. Week 1: Month-end close, R&D accruals and grant cost allocation completed with your bookkeeper.
2. Week 2: Runway, budget-versus-actual and program spend reviewed with the CEO.
3. Week 3: Project work: fundraising model updates, vendor negotiations, grant reports or audit preparation.
4. Week 4: Board or investor update prepared; forecasts refreshed for the months ahead.

This cadence follows our fractional CFO onboarding process, adapted for life sciences companies.

Running Better Board Meetings

Board meetings are where founders build — or lose — investor confidence. A strong financial section shows cash position, runway, burn versus budget, program spend, hiring progress and any changes to the milestone timeline, with a short explanation of every significant variance. It also looks ahead: the next funding need, risks to the plan and decisions the board must make.

A fractional CFO for biotech startups prepares this package every quarter (or monthly for more active boards), presents the financials directly when helpful and prepares founders for the tough questions experienced directors will ask. Consistent, transparent reporting turns the board from an audience you have to manage into a group of advisors who help you win.

Good board reporting also creates a written record of decisions, approvals and assumptions. That record becomes invaluable during the next financing, when new investors review how the company has been governed and whether management has delivered against its plans.

Common Financial Mistakes Biotech Founders Make

• Calculating runway from the bank balance alone: ignoring committed contracts and planned hires.
• Raising too little: funding the milestone with no buffer for scientific or timeline risk.
• Starting the raise too late: biotech rounds often take many months to close.
• Weak grant accounting: mixing grant and non-grant costs, leading to disallowed expenses.
• Missing R&D credits: leaving valuable cash unclaimed.
• Messy cap tables: undocumented option grants or convertible terms that surface during diligence.
• Cash-basis books: financial statements that don’t reflect true R&D spend and can’t be audited.

How to Choose the Right Fractional CFO for Biotech Startups

When evaluating a fractional CFO for biotech startups, look for someone who can speak both finance and science. Ask:

• Have you worked with pre-revenue life sciences companies?
• How do you build milestone-based budgets and runway models?
• Do you have experience with SBIR/STTR grant accounting?
• How do you handle CRO and CDMO accruals?
• Have you supported venture fundraising and investor due diligence?
• Can you prepare the company for a first audit?

You may also find our comparison of a fractional CFO agency vs freelancer helpful, and startups building software alongside their science can read our fractional CFO for SaaS companies guide.

Why Life Sciences Founders Choose Nadeem Academy

Frequently Asked Questions

Give Your Science the Runway It Deserves

Breakthrough science takes time, and time costs money. The biotech companies that succeed aren’t only the ones with the best data; they are the ones that manage capital wisely, hit milestones on budget and earn the trust of investors. With disciplined financial leadership, your team can stay focused on the lab while the business side is handled with care.

A fractional CFO for biotech startups gives you that leadership, with accurate runway, smarter fundraising, maximized non-dilutive funding and audit-ready books, without the cost or equity of a full-time executive.